5-Amino-1-Methylquinolinium Clinical Trial

Direct Answer: Current Clinical Trial Status of 5-Amino-1-Methylquinolinium

As of current public clinical registries, 5-amino-1-methylquinolinium has not completed formal FDA-registered phase II or phase III human clinical trials for clinical therapeutics. The vast majority of published data surrounding 5-amino-1-methylquinolinium clinical trial inquiries stems from foundational preclinical rodent models, ex vivo tissue assays, and in vitro cellular research evaluating cytosolic nicotinamide N-methyltransferase (NNMT) inhibition.

While non-human rodent studies have demonstrated targeted alterations in energy expenditure and intracellular nicotinamide adenine dinucleotide (NAD+) salvage pathways, 5-amino-1-methylquinolinium remains strictly classified as an investigational research compound for laboratory use. Researchers acquiring 5-amino-1mq must evaluate it exclusively within controlled in vitro assays or preclinical animal models to map its precise biochemical mechanisms without extrapolating unverified human clinical outcomes.

Biochemical Mechanism: NNMT Inhibition and NAD+ Salvage Dynamics

Nicotinamide N-methyltransferase (NNMT) is a cytosolic enzyme responsible for catalyzing the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide (NAM), producing 1-methylnicotinamide (MNA) and S-adenosylhomocysteine (SAH). In metabolic tissue, elevated NNMT activity depletes the pool of available NAM and SAM, effectively dampening the efficiency of the NAD+ salvage pathway and altering epigenetic methylation reactions.

5-Amino-1-methylquinolinium functions as a membrane-permeable, small-molecule competitive inhibitor designed specifically to target the active site of NNMT. By blocking NNMT activity, in vitro assays show a restoration of intracellular NAD+ concentrations and an increase in SAM availability. Investigators utilizing our comprehensive research hub often explore how NNMT inhibition downstream regulates SIRT1 expression and poly(ADP-ribose) polymerase (PARP) enzymatic activity in adipocyte and skeletal muscle cell lines.

Preclinical Literature Findings: Rodent Models and Adipocyte Research

Primary preclinical literature regarding 5-amino-1-methylquinolinium focuses on diet-induced obesity (DIO) rodent models. In these controlled settings, researchers administered 5-amino-1-methylquinolinium to observe changes in basal metabolic rate, adipocyte hypertrophy, and systemic glucose tolerance without observed changes in cumulative food intake.

Preclinical data indicate that targeted NNMT suppression in white adipose tissue (WAT) promotes an increase in oxygen consumption rates and intracellular ATP generation. In vitro experiments on cultured 3T3-L1 adipocytes further demonstrate reduced lipid accumulation and downregulated lipogenic gene expression. These findings provide a biological rationale for ongoing nnmt inhibitors metabolic research, though researchers must strictly distinguish between preclinical rodent models and human clinical validation.

Comparing Metabolic Research Targets: NNMT Inhibitors vs. Mitochondrial Peptides

When designing protocols to investigate cellular energy regulation, principal investigators often compare small-molecule NNMT inhibitors with mitochondrial-derived peptides or growth hormone secretagogues. While 5-amino-1-methylquinolinium acts directly on cytosolic methyltransferase enzymes to preserve NAD+ precursor availability, alternative agents modulate metabolic pathways through distinct signaling cascades.

For example, researchers investigating broader mitochondrial signaling dynamics may incorporate motsc mitochondrial peptides to assess AMPK activation and systemic insulin sensitivity in skeletal muscle assays. Alternatively, studies focused on somatotropic axis regulation and body composition often utilize GH-releasing peptides such as cjc-1295 dac. Understanding the distinct enzymatic target of 5-amino-1-methylquinolinium relative to peptide-based signaling agonists allows laboratories to establish precise, complementary research frameworks.

Regulatory Classification and Research-Use-Only Mandates

Because 5-amino-1-methylquinolinium has not undergone approval by the U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA) for human consumption, it is strictly classified as a research compound. It is distributed strictly for in vitro laboratory experiments, enzymatic assays, and approved animal research models.

Suppliers claiming human clinical trial verification or offering dosing instructions for human subjects violate regulatory standards and compromise scientific integrity. All laboratory personnel acquiring research compounds should ensure that reagents are procured strictly through accredited institutional channels for non-human research applications.

Quality Verification: HPLC, Mass Spectrometry, and COA Benchmarks

Maintaining high reproducibility in preclinical models requires rigorous purity standards for small-molecule inhibitors. Impurities or residual synthesis byproducts can cause off-target cytotoxicity in cell culture or confound metabolic data in animal models. Therefore, every lot of 5-amino-1-methylquinolinium must undergo comprehensive analytical validation prior to experimental deployment.

PX1 Research enforces strict quality protocols by subjecting every lot to independent, ISO 17025-accredited third-party testing. Analytical parameters must meet the following criteria:

• Purity Verification: High-Performance Liquid Chromatography (HPLC) confirming ≥98.0% chemical purity. • Mass Spectrometry (MS): Electrospray ionization mass spectrometry (ESI-MS) confirming exact molecular mass and chemical identity. • Endotoxin Assay: Limulus Amebocyte Lysate (LAL) testing ensuring endotoxin levels remain below strictly monitored research thresholds (<0.01 EU/mg). • Certificate of Analysis (COA): Lot-specific analytical reports provided transparently with every order.

Laboratory Reconstitution, Solubility, and Handling Guidelines

5-Amino-1-methylquinolinium is typically supplied as a lyophilized salt (e.g., bromide or iodide salt) to maximize solid-state stability. Achieving complete solubilization is critical for accurate working concentrations in cell culture assays and animal administration protocols.

Laboratory handling recommendations include:

1. Solvent Selection: Highly soluble in sterile dimethyl sulfoxide (DMSO) or sterile aqueous buffers (such as phosphate-buffered saline, PBS) depending on final assay solvent tolerances. 2. Stock Solution Preparation: Reconstitute under a laminar flow hood using sterile techniques. Gentle vortexing or sonication may be applied to dissolve dense salt crystals. 3. Aliquoting: To avoid repeated freeze-thaw cycles that destabilize the compound in solution, prepare single-use working aliquots. 4. Storage Conditions: Store desiccated solid powder at -20°C. Resuspended liquid aliquots should be stored at -80°C for long-term stability.

Procurement and Institutional Supply Chain Validation

For academic laboratories, biotechnology firms, and institutional research facilities, establishing a reliable supply chain is critical to experimental consistency. Variations between unverified commercial lots can introduce experimental artifacts that compromise data integrity.

PX1 Research manufactures small molecules and peptides in state-of-the-art, GMP-compliant domestic facilities located in the United States. Orders are shipped directly from centralized distribution centers in California and Arizona, offering same-day shipping for orders placed Monday through Friday. Laboratories requiring large-scale allocations or recurring institutional fulfillment can access customized purchasing tiers via our wholesale accounts portal.